HMV Wealth Advisors LLC Has $418,000 Stock Position in Stryker Corporation $SYK

Key Points

• HMV Wealth Advisors LLC reduced its stake in Stryker Corporation by 54.8% during the second quarter, leaving them with a stock position worth $418,000.
• Stryker's recent earnings report showed an EPS of $3.13 and revenue of $6.02 billion, exceeding analyst expectations.
• The company declared a quarterly dividend of $0.84 per share, with a yield of 0.9%, set to be paid on October 31st.

HMV Wealth Advisors LLC cut its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 54.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,056 shares of the medical technology company's stock after selling 1,279 shares during the period. HMV Wealth Advisors LLC's holdings in Stryker were worth $418,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in SYK. Mogy Joel R Investment Counsel Inc. boosted its stake in shares of Stryker by 3.4% during the 1st quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after buying an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. raised its holdings in Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after acquiring an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new position in Stryker during the first quarter valued at approximately $1,840,000. Mar Vista Investment Partners LLC grew its stake in Stryker by 10.2% in the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock valued at $33,572,000 after purchasing an additional 8,353 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in shares of Stryker during the 1st quarter worth approximately $2,857,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SYK. Redburn Partners set a $420.00 target price on shares of Stryker in a research note on Thursday, September 18th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Stryker in a research note on Saturday, September 27th. Rothschild Redb upgraded shares of Stryker to a "hold" rating in a research note on Thursday, September 18th. Wall Street Zen cut shares of Stryker from a "buy" rating to a "hold" rating in a report on Friday, September 26th. Finally, BTIG Research reiterated a "buy" rating on shares of Stryker in a report on Monday, July 14th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Stryker presently has a consensus rating of "Moderate Buy" and a consensus price target of $430.33.

Stryker Stock Down 1.2%

Shares of SYK opened at $365.99 on Tuesday. The firm has a market cap of $139.92 billion, a P/E ratio of 48.48, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The firm's 50-day simple moving average is $382.13 and its 200 day simple moving average is $378.92.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Insiders Place Their Bets

In other news, insider Viju Menon sold 500 shares of the business's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.